TY - JOUR
T1 - A hollow-core, magnetic, and mesoporous double-shell nanostructure
T2 - In situ decomposition/reduction synthesis, bioimaging, and drug-delivery properties
AU - Wu, Huixia
AU - Zhang, Shengjian
AU - Zhang, Jiamin
AU - Liu, Gang
AU - Shi, Jianlin
AU - Zhang, Lingxia
AU - Cui, Xiangzhi
AU - Ruan, Meiling
AU - He, Qianjun
AU - Bu, Wenbo
PY - 2011/5/24
Y1 - 2011/5/24
N2 - A novel in situ decomposition/reduction approach is developed to manufacture hollow core, magnetic, and mesoporous double-shell nanostructures (HMMNSs) via in situ decomposition and reduction of a β-FeOOH nanorod core and organosilicate-incorporated silica-shell precursor. The formed HMMNSs are then aminated by silanization for further covalent conjugation to rhodamine B isothiocyanate (RBITC) and poly(ethylene glycol) (PEG) chains. The resultant RBITC-grafted and PEGylated nanocomposites (HMMNS-R/Ps) have excellent blood compatibility and very low cytotoxicity towards HeLa and MCF-7 cells, and can be taken up by cancer cells effectively in a dose-dependent manner, as confirmed by in vitro flow cytometry, confocal luminescence imaging, and magnetic resonance imaging (MRI) studies. In vivo MRI studies coupled with Prussian blue staining of slides from different organs show that the nanocomposites preferentially accumulate in liver and spleen after intravenous injection, which suggests a potential application of the nanocomposites as MRI contrast agents. Importantly, the HMMNS-R/P nanocomposites show high loading capacity for water-insoluble anticancer drugs (docetaxel or camptothecin) owing to the presence of a large inner cavity and enhanced surface area and pore volume. Furthermore, the drug-loaded nanocomposites exhibit greater cytotoxicity than the corresponding free drugs. These results confirm that the HMMNS-R/P nanocomposites are promising candidates for simultaneous bioimaging and drug delivery.
AB - A novel in situ decomposition/reduction approach is developed to manufacture hollow core, magnetic, and mesoporous double-shell nanostructures (HMMNSs) via in situ decomposition and reduction of a β-FeOOH nanorod core and organosilicate-incorporated silica-shell precursor. The formed HMMNSs are then aminated by silanization for further covalent conjugation to rhodamine B isothiocyanate (RBITC) and poly(ethylene glycol) (PEG) chains. The resultant RBITC-grafted and PEGylated nanocomposites (HMMNS-R/Ps) have excellent blood compatibility and very low cytotoxicity towards HeLa and MCF-7 cells, and can be taken up by cancer cells effectively in a dose-dependent manner, as confirmed by in vitro flow cytometry, confocal luminescence imaging, and magnetic resonance imaging (MRI) studies. In vivo MRI studies coupled with Prussian blue staining of slides from different organs show that the nanocomposites preferentially accumulate in liver and spleen after intravenous injection, which suggests a potential application of the nanocomposites as MRI contrast agents. Importantly, the HMMNS-R/P nanocomposites show high loading capacity for water-insoluble anticancer drugs (docetaxel or camptothecin) owing to the presence of a large inner cavity and enhanced surface area and pore volume. Furthermore, the drug-loaded nanocomposites exhibit greater cytotoxicity than the corresponding free drugs. These results confirm that the HMMNS-R/P nanocomposites are promising candidates for simultaneous bioimaging and drug delivery.
KW - blood compatibility
KW - drug delivery
KW - magnetic resonance imaging
KW - magnetite
KW - mesoporous silica
UR - https://www.scopus.com/pages/publications/79956104071
U2 - 10.1002/adfm.201002337
DO - 10.1002/adfm.201002337
M3 - 文章
AN - SCOPUS:79956104071
SN - 1616-301X
VL - 21
SP - 1850
EP - 1862
JO - Advanced Functional Materials
JF - Advanced Functional Materials
IS - 10
ER -
